Grifols, S.A. (GRFS)
NASDAQ: GRFS · IEX Real-Time Price · USD
6.79
+0.36 (5.60%)
At close: May 1, 2024, 4:00 PM
6.73
-0.06 (-0.88%)
After-hours: May 1, 2024, 7:18 PM EDT
Grifols Employees
Grifols had 23,737 employees on December 31, 2023. The number of employees decreased by 2,577 or -9.79% compared to the previous year.
Employees
23,737
Change (1Y)
-2,577
Growth (1Y)
-9.79%
Revenue / Employee
$308,565
Profits / Employee
$2,776
Market Cap
5.72B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 23,737 | -2,577 | -9.79% |
Dec 31, 2022 | 26,314 | 3,080 | 13.26% |
Dec 31, 2021 | 23,234 | -421 | -1.78% |
Dec 31, 2020 | 23,655 | -348 | -1.45% |
Dec 31, 2019 | 24,003 | 2,773 | 13.06% |
Dec 31, 2018 | 21,230 | 2,934 | 16.04% |
Dec 31, 2017 | 18,296 | 3,419 | 22.98% |
Dec 31, 2016 | 14,877 | 140 | 0.95% |
Dec 31, 2015 | 14,737 | 757 | 5.41% |
Dec 31, 2014 | 13,980 | 2,201 | 18.69% |
Dec 31, 2013 | 11,779 | 671 | 6.04% |
Dec 31, 2012 | 11,108 | -122 | -1.09% |
Dec 31, 2011 | 11,230 | 5,262 | 88.17% |
Dec 31, 2010 | 5,968 | -16 | -0.27% |
Dec 31, 2009 | 5,984 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
R1 RCM | 30,000 |
Bausch + Lomb | 13,300 |
Option Care Health | 7,802 |
Ionis Pharmaceuticals | 927 |
Glaukos | 907 |
Apellis Pharmaceuticals | 702 |
Blueprint Medicines | 655 |
ImmunityBio | 628 |
GRFS News
- 12 days ago - Grifols 2023 Annual Report on Form 20-F filed with the SEC - PRNewsWire
- 13 days ago - Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. - GlobeNewsWire
- 14 days ago - IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 17 days ago - Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper - Reuters
- 21 days ago - Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake - Reuters
- 23 days ago - INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 27 days ago - Spain's Grifols gives new details on past EBITDA, leverage ratios to supervisor - Reuters
- 27 days ago - Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening - GlobeNewsWire